[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0608261T3 - Sammensætninger med immunreaktivt hepatitis C virus polypeptid - Google Patents

Sammensætninger med immunreaktivt hepatitis C virus polypeptid

Info

Publication number
DK0608261T3
DK0608261T3 DK92919917T DK92919917T DK0608261T3 DK 0608261 T3 DK0608261 T3 DK 0608261T3 DK 92919917 T DK92919917 T DK 92919917T DK 92919917 T DK92919917 T DK 92919917T DK 0608261 T3 DK0608261 T3 DK 0608261T3
Authority
DK
Denmark
Prior art keywords
compositions
immunoreactive
hepatitis
virus polypeptide
methods
Prior art date
Application number
DK92919917T
Other languages
Danish (da)
English (en)
Inventor
Michael Houghton
Amy J Weiner
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0608261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DK0608261T3 publication Critical patent/DK0608261T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK92919917T 1991-09-13 1992-09-11 Sammensætninger med immunreaktivt hepatitis C virus polypeptid DK0608261T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75957591A 1991-09-13 1991-09-13
PCT/US1992/007683 WO1993006126A1 (en) 1991-09-13 1992-09-11 Immunoreactive hepatitis c virus polypeptide compositions

Publications (1)

Publication Number Publication Date
DK0608261T3 true DK0608261T3 (da) 2003-03-17

Family

ID=25056174

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92919917T DK0608261T3 (da) 1991-09-13 1992-09-11 Sammensætninger med immunreaktivt hepatitis C virus polypeptid

Country Status (16)

Country Link
US (6) US5756312A (ro)
EP (1) EP0608261B1 (ro)
JP (5) JPH06511149A (ro)
AT (1) ATE228564T1 (ro)
AU (1) AU679429B2 (ro)
BG (1) BG62973B1 (ro)
CA (1) CA2116764C (ro)
DE (1) DE69232859T2 (ro)
DK (1) DK0608261T3 (ro)
ES (1) ES2182822T3 (ro)
FI (1) FI112438B (ro)
HU (1) HU227510B1 (ro)
PL (2) PL171489B1 (ro)
RO (1) RO116199B1 (ro)
RU (2) RU2212899C2 (ro)
WO (1) WO1993006126A1 (ro)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
DE69332485T2 (de) * 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
DE69435023T2 (de) * 1993-04-27 2008-09-11 N.V. Innogenetics S.A. Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimittel und diagnostika
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
EP1421951A3 (en) 1993-05-12 2005-10-05 Chiron Corporation Conserved motif of hepatitis C virus E2/NS1 region
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
DE69434295T2 (de) * 1993-11-04 2006-02-16 Innogenetics N.V. Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
DE59511054D1 (de) 1994-07-25 2006-08-10 Roche Diagnostics Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
SG71728A1 (en) 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EP0804584B2 (en) 1994-10-21 2008-07-09 Innogenetics N.V. Sequences of hepatitis c virus genotype 7 and their use as prophylactic, therapeutic and diagnostic agents
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7045363B2 (en) * 1996-05-01 2006-05-16 Fujirebio Inc. Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide
US6001613A (en) * 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
WO1998021338A1 (en) 1996-11-08 1998-05-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US6322965B1 (en) * 1997-02-10 2001-11-27 Advanced Life Science Institute, Inc. Chimera antigen peptide
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
AU752131C (en) * 1997-11-06 2003-12-04 Innogenetics N.V. Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
DE69938062T2 (de) * 1998-12-31 2009-01-15 Novartis Vaccines and Diagnostics, Inc., Emeryville Modifizierte hiv env polypeptide
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1535628B1 (en) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-like particle
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
AU2001261758B2 (en) * 2000-07-19 2005-07-21 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
KR20070114209A (ko) 2000-08-17 2007-11-29 트리펩 아베 리바비린 함유 백신 및 이것의 사용 방법
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2001292667A1 (en) 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
EP2292772A1 (en) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
EP1427806A4 (en) * 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2525825A1 (en) 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
WO2005010035A2 (en) * 2003-07-22 2005-02-03 Branch Andrea D Alternate reading frame polypeptides derived from hepatitis c and methods of their use
WO2005017125A2 (en) * 2003-08-14 2005-02-24 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-c virus
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
EP2266602A3 (en) 2004-11-01 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
EP1888751A2 (en) * 2005-05-25 2008-02-20 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc HETERO DUPLEX TRACKING TEST
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2201023A2 (en) * 2007-09-14 2010-06-30 GENimmune N.V. Affinity tag
KR102271404B1 (ko) 2007-09-28 2021-07-02 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
EP3121271B1 (en) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
JP6120839B2 (ja) 2011-07-06 2017-04-26 ノバルティス アーゲー カチオン性水中油型エマルジョン
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
US9228006B2 (en) 2012-03-16 2016-01-05 University Health Network Methods and compositions for modulating Toso activity
RU2520710C1 (ru) * 2012-12-10 2014-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EP3565834A1 (en) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
CA3049105A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Dnabii vaccines and antibodies with enhanced activity
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400079A1 (de) * 1984-01-03 1985-07-11 Röhm GmbH, 6100 Darmstadt Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
DE69033891T2 (de) * 1989-05-18 2002-08-29 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika: Polynukleotide, geeignet für Reihenuntersuchungen auf Hepatitis C-Virus
WO1991004262A1 (en) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
DE59109221D1 (de) * 1990-11-03 2001-11-15 Dade Behring Marburg Gmbh HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions

Also Published As

Publication number Publication date
RU2212899C2 (ru) 2003-09-27
BG98653A (bg) 1995-05-31
US5728520A (en) 1998-03-17
JPH06511149A (ja) 1994-12-15
ES2182822T3 (es) 2003-03-16
AU2643692A (en) 1993-04-27
WO1993006126A1 (en) 1993-04-01
ATE228564T1 (de) 2002-12-15
JP2008133301A (ja) 2008-06-12
HU9400741D0 (en) 1994-06-28
JP2005176853A (ja) 2005-07-07
DE69232859T2 (de) 2003-04-10
US5670152A (en) 1997-09-23
CA2116764A1 (en) 1993-04-01
US5756312A (en) 1998-05-26
RU2136311C1 (ru) 1999-09-10
HU227510B1 (en) 2011-07-28
US5670153A (en) 1997-09-23
FI941199A (fi) 1994-04-27
DE69232859D1 (de) 2003-01-16
US6303292B1 (en) 2001-10-16
US5766845A (en) 1998-06-16
JP4353905B2 (ja) 2009-10-28
FI941199A0 (fi) 1994-03-14
JP2004073207A (ja) 2004-03-11
JP2002167336A (ja) 2002-06-11
BG62973B1 (bg) 2000-12-29
FI112438B (fi) 2003-12-15
AU679429B2 (en) 1997-07-03
EP0608261A4 (en) 1995-03-15
PL171972B1 (pl) 1997-07-31
CA2116764C (en) 1999-12-07
EP0608261B1 (en) 2002-11-27
RO116199B1 (ro) 2000-11-30
HUT67342A (en) 1995-03-28
EP0608261A1 (en) 1994-08-03
PL171489B1 (pl) 1997-05-30

Similar Documents

Publication Publication Date Title
DK0608261T3 (da) Sammensætninger med immunreaktivt hepatitis C virus polypeptid
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
FI932561A (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
ATA257190A (de) Virales polypeptid
ATE496630T1 (de) Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten
DK643387D0 (da) T-celle-epitoper af hepatitis b-virus-nucleocapsid-protein
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
DK139083D0 (da) Sma peptider med specificiteten af mund- og klovesyge virale antigener
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
DK88988D0 (da) T- og b-celleepitoper af pre-s-regionen af hepatitis-b-virus-overfladeantigen
ATE174625T1 (de) Rekombinante hybride porinepitope
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
NO983054L (no) Virale rekombinante pseudopartikler og anvendelse som vaksiner og som anti-tumormiddel
DK196689A (da) Ekspression af praes2-proteinet for hepatitis b i methylotrophe gaerarter
EP0485347A3 (en) Recombinant hepatitis delta antigen, process for the purification and use thereof
DE59209899D1 (de) Rekombinante Proteine mit der Immunreaktivität des Hepatitis B Virus e Antigens (HBeAg), Verfahren zu ihrer Herstellung und ihre Verwendung in Immunoassays und Impfstoffen
PL273721A1 (en) Method of obtaining a polypeptide exhibiting antigenic properties in respect to the pre s1 region of hepatitis virus a areole